BioTech 365

DECEMBER 23, 2020

Isatuximab, Sold Under the Brand Name Sarclisa: A Monoclonal Antibody Medication for the Treatment of Multiple Myeloma – Emerging Insights and Market Forecasts 2020-2030 – ResearchAndMarkets.com Isatuximab, Sold Under the Brand Name Sarclisa: A Monoclonal Antibody Medication for the Treatment … Continue reading →

Branding 40

Branding Antibody Marketing 40

Pharmaceutical Technology

JANUARY 23, 2023

Additionally, Roche also markets MMF (under the brand name CellCept), an off-label immunosuppressive agent that is commonly prescribed to SLE and LN patients, although generic versions of MMF are also available throughout the 7MM.

Marketing 278

Marketing Production Drugs Trials 278

pharmaphorum

SEPTEMBER 16, 2022

Sanofi and AstraZeneca are closing in on EU approval of nirsevimab, their long-acting antibody for the protection of newborns and infants from respiratory syncytial virus (RSV) infections. The post CHMP says yes to Sanofi/AstraZeneca antibody for RSV prevention appeared first on. Evusheld also backed for COVID-19.

Antibody 59

Antibody Vaccination Vaccine Marketing 59

Scienmag

MAY 20, 2021

Montréal, May 20, 2021–Researchers at the University of Montreal Hospital Research Centre (CRCHUM) and Yale University have succeeded in reducing the size of the HIV reservoir in humanized mice by using a “molecular can opener” and a combination of antibodies found in the blood of infected individuals.

Branding 53

Branding Antibody Research Allergies 53

Pharmaceutical Technology

MAY 19, 2023

Roche’s anti-CD20 monoclonal antibody Rituxan/MabThera (rituximab) is one of the most successful oncology drugs of all time. However, there is also competition with subcutaneous branded rituximab, which cannibalises Rituxan and complicates this assumption. Rituxan’s success made it a prime target for biosimilar developers.

Sales 147

Sales Production Marketing FDA Approval 147

Pharmaceutical Technology

NOVEMBER 9, 2022

Known by the brand name Roctavian, BioMarin’s haemophilia A therapy valoctocogene roxaparvovec could be fairly priced in the range of $1.95–1.96 On November 2, the Institute for Clinical and Economic Review (ICER) released its updated evidence aimed at measuring the clinical effectiveness and cost of the two haemophilia gene therapies.

Gene Therapy 278

Gene Therapy Gene FDA Approval Medicine 278

XTalks

JANUARY 20, 2025

This strategic move transformed Actavis into one of the largest pharma companies globally, with a strong presence across branded, generic and over-the-counter (OTC) medicines. Following the merger, Actavis rebranded itself as Allergan, leveraging the strong recognition of Allergans brand.

Marketing 104

Marketing Botox Life Science Pharma Companies 104

Pharmaceutical Technology

SEPTEMBER 15, 2022

The increase in the production of biological drugs such as vaccines, gene and cell therapies, and monoclonal antibodies, is increasing the volume of injectable drug products in the global healthcare market.

Marketing 100

Marketing Containment Production Sales 100

pharmaphorum

OCTOBER 6, 2022

Fresh with a new brand identity, the France-headquartered pharma group has pledged to grow its oncology sales from its current objective of €1 billion in 2025 to €3 billion in 2030, continuing a diversification of its business from its traditional focus on cardiovascular diseases. billion and $1.8

Sales 98

Sales Drugs Branding Antibody 98

The Pharma Data

MAY 27, 2022

Roche today announced that new pivotal data on its investigational CD20xCD3 T-cell engaging bispecific antibody, glofitamab, will be presented for the first time at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting from 3-7 June and the European Hematology Association (EHA) 2022 Congress from 9-12 June.

Antibody 52

Antibody In-Vitro Medicine Engineer 52

pharmaphorum

SEPTEMBER 2, 2022

German drugmaker Boehringer Ingelheim has its first regulatory approval for spesolimab, its antibody therapy for rare and life-threatening skin disorder generalised pustular psoriasis (GPP), in the US.

Drugs 105

Drugs Antibody FDA Approval Trials 105

BioSpace

NOVEMBER 3, 2022

Regeneron called it quits on an experimental osteoarthritis pain treatment that has raised safety flags and an experimental antibody for cat-allergic asthma.

Antibody 53

Antibody Branding Vaccine Vaccination 53

pharmaphorum

MARCH 15, 2022

Sarclisa is a CD38-directed antibody that is currently approved as an intravenous therapy for relapsed multiple myeloma in combination with either Bristol-Myers Squibb’s Pomalyst (pomalidomide) plus dexamethasone or Amgen’s Kyprolis (carfilzomib) plus dexamethasone.

Trials 97

Trials Sales Drug Delivery Antibody 97

pharmaphorum

SEPTEMBER 17, 2020

There are two antibodies already on the market that target PCSK9 – Amgen’s Repatha (evolocumab) and Sanofi/Regeneron’s Repatha (alirocumab) – but these require subcutaneous injection every two to four weeks. Novartis paid a hefty $9.7 The post AZ buys oral PCSK9 cholesterol drug from Dogma Therapeutics appeared first on.

Drugs 66

Drugs Antibody Sales Branding 66

pharmaphorum

APRIL 7, 2021

billion DKK ($672 million) from AbbVie after the companies struck an R&D deal to research epcoritamab, a bispecific antibody targeting CD3 and CD20 that the biotech developed in-house. With other drugs in the pipeline too, van de Winkel said the company aims to continue to break new ground with next-generation antibody-based therapies.

Antibody 92

Antibody Life Science Development Drugs 92

pharmaphorum

AUGUST 17, 2020

The FDA has approved Roche’s satralizumab for the rare autoimmune disorder Neuromyelitis Optica Spectrum Disorder (NMOSD), under the brand name Enspryng. The big Swiss pharma had been hoping for approva l in patients regardless of whether they have anti-aquaporin-4 (AQP4) antibodies.

FDA Approval 66

FDA Approval Antibody Branding Trials 66

XTalks

OCTOBER 22, 2021

Boehringer Ingelheim’s Cyltezo has become the second interchangeable biosimilar approved by the FDA, and the first approved interchangeable monoclonal antibody. The shorter approval time for generics along with the shorter time for development make the cost to consumers significantly lower than branded drugs.

FDA Approval 98

FDA Approval Production Insulin Antibody 98

pharmaphorum

MARCH 30, 2022

Sanofi has agreed another deal to flesh out its R&D pipeline, paying IGM Biosciences $150 million upfront to gain access to its engineered IgM antibody technology across six targets in oncology and immunology/inflammation. Also on the table are 50:50 profit-sharing arrangements in some markets for the oncology assets. So why IgM?

Antibody 52

Antibody Engineer Branding Development 52

The Pharma Data

JANUARY 29, 2021

(MedMira) (TSXV: MIR) announces the development of a rapid antibody test prototype that detects the presence of the neutralizing antibodies against the SARS-CoV-2 virus. The Company’s tests are sold globally under the Reveal ® , Multiplo ® and Miriad ® brands.

Production 52

Production Antibody Manufacturing Development 52

Find Me Cure

APRIL 23, 2020

Vandalizing cell towers is not going to get rid of this new virus in the corona family and avoiding certain brands of beer is not a good prevention strategy. . This means that in order for herd immunity to work, 50-70% of the world population needs to get infected and then develop antibodies. .

Immune Response 117

Immune Response Antibody Scientist Development 117

pharmaphorum

FEBRUARY 9, 2022

GlaxoSmithKline’s COVID-19 products – antibody drug Xevudy and a vaccine adjuvant – helped drive a 5% increase in 2021 revenues to £34 billion ($46 billion), ahead of what chief executive Emma Walmsley says will be a “landmark year” for the company. Last year, sales at the JV stabilised at £9.6 billion but have been.

Sales 105

Sales Production Vaccination Vaccine 105

pharmaphorum

APRIL 20, 2021

The cost-effectiveness agency has said that anti-CD20 antibody Kesimpta (ofatumumab) can be prescribed via the NHS in England and Wales as a treatment for adults with RMS with active disease, as either a first-line therapy or after alternative drugs have been tried. It was backed by NICE for NHS use in July 2018.

Sales 111

Sales Medicine Drugs Marketing 111

pharmaphorum

FEBRUARY 25, 2021

Already marketed in Europe under the brand names TicoVac and FSME-Immun, the shot is based around an inactivated whole virus vaccine. The vaccine causes the body to make neutralising antibodies against the natural TBE virus as it looks almost identical biologically to the one that causes the disease.

Vaccination 66

Vaccination Vaccine Antibody Clinical Trials 66

pharmaphorum

MARCH 28, 2022

Polivy – an antibody-drug conjugate targeting CD79b – is the first drug to significantly improve outcomes in this disease in more than 20 years, said Roche, which has previously predicted that approval in the first-line setting could expand sales to around $2 billion a year.

Drugs 52

Drugs Antibody Sales Branding 52

XTalks

JANUARY 9, 2024

In the US, some of the brand names that levothyroxine is sold under include Synthroid (from AbbVie), Levoxyl (Pfizer) and Tirosint (by Swiss manufacturer IBSA Institut Biochimique). Blocking BAFF interaction : Belimumab, which is an anti-BAFF monoclonal antibody in a Phase II trial. The thyroid disease market is huge, and lucrative.

Hormones 105

Hormones Antibody Trials Production 105

pharmaphorum

DECEMBER 18, 2020

Originally approved in 2011 as an IV therapy for adults with SLE, a debilitating autoimmune disease, GSK got a green light for the subcutaneous formulation in 2017 and last year extended the label of the antibody to include paediatric patients aged over five.

FDA Approval 99

FDA Approval Contract Manufacturing Sales Trials 99

pharmaphorum

OCTOBER 22, 2020

” Roche has been studying its already-approved anti-inflammatory drug Actemra (tocilizumab), branded as RoActemra in some countries, to see if it can cut the chances of COVID patients needing a ventilator.

Development 66

Development Branding RNA Manufacturing 66

pharmaphorum

MARCH 31, 2021

Meanwhile, Novartis has secured European approval for a subcutaneous formulation of the anti-CD20 antibody ofatumumab for relapsing forms of multiple sclerosis (RMS) under the Kesimpta brand name. . “We believe this technology has the potential to transform many patients’ lives,” she added. Kesimpta approval in Europe.

Licensing 98

Licensing Licensing Gene Therapy Sales 98

STAT News

NOVEMBER 18, 2022

The monoclonal antibody teplizumab, which will be marketed under the brand name Tzield and is from ProventionBio and Sanofi, is given through intravenous infusion. The first therapy that delays the onset of type 1 diabetes received approval from the U.S. Food and Drug Administration , CNN tells us.

Insulin 98

Insulin FDA Approval Production Pharmacy 98

pharmaphorum

SEPTEMBER 19, 2021

AstraZeneca and Daiichi Sankyo were clearly excited by data from a trial pitting their HER2 antibody-drug conjugate (ADC) Enhertu against Roche’s rival Kadcyla when they reported top-line results last month – and a look at the full data set reveals why.

Sales 105

Sales Trials Drugs Licensing 105

XTalks

OCTOBER 27, 2021

Ranibizumab is an anti-angiogenic monoclonal antibody fragment that targets vascular endothelial growth factor A (VEGF A). Ranibizumab was developed by Genentech and is sold under the brand name Lucentis. It received FDA approval in 2018. The ocular implant is the size of a grain of rice that is placed in the upper lid of the eye.

Drug Delivery Systems 104

Drug Delivery Systems Drug Delivery FDA Approval Drugs 104

The Pharma Data

DECEMBER 30, 2020

billion acquisition of immuno-oncology company Forty Seven and its lead asset, magrolimab, a monoclonal antibody in the clinic for several cancers, including myelodysplastic syndrome (MDS), acute myeloid leukemia (AML) and diffuse large B-cell lymphoma (DLBCL). It began in May with the $4.9 Magrolimab targets CD47. Most Read Today.

Antibody 52

Antibody Allergies Branding Dermatology 52

The Pharma Data

JANUARY 20, 2021

Dr Joerg Windisch, CEO of Polpharma Biologics, said “Our new brand represents our passion and dedication to innovation, we utilize the latest technology and cutting-edge techniques to discover and advance ground breaking biologics to the clinic, whether this is our own pipeline or that of our partners. This press release features multimedia.

Branding 52

Branding Manufacturing Production Containment 52

pharmaphorum

OCTOBER 24, 2022

The CTLA4 inhibitor – now given the brand name Imjudo – is only the second drug in the class to be approved after Bristol-Myers Squibb’s well-established Yervoy (ipilimumab), which is used alongside BMS’ PD-1 inhibitor Opdivo (nivolumab) in several solid tumours, including HCC and lung, colorectal, skin, and kidney cancers. .

Drugs 85

Drugs FDA Approval Branding Antibody 85

XTalks

MAY 13, 2021

Taking advantage of the opportunity, the top ten pharma brands spent 17 percent more on TV ads in April 2020 compared to just a month prior, raising their monthly ad expenditures from $156 million to $183 million. When a lot of brands are advertising simultaneously, linear TV helps you maintain awareness across your audience segment.”.

Insulin 104

Insulin Marketing Drugs Branding 104

pharmaphorum

DECEMBER 29, 2021

Sanofi and Regeneron have another challenger to their big-selling drug Dupixent for atopic dermatitis, now that the FDA has approved Leo Pharma’s rival antibody tralokinumab. It continues to grow strongly with Sanofi reporting a 53% rise in sales to more than $4.1

Sales 111

Sales Dermatology Marketing Allergies 111

pharmaphorum

SEPTEMBER 20, 2022

The phase 1/3 ROSALIA study showed that the copycat denosumab matched Amgen’s brand on multiple pharmacokinetics, pharmacodynamics, efficacy, safety, and immunogenicity measures in postmenopausal women with osteoporosis, said Sandoz in a statement. billion TNF inhibitor Enbrel (etanercept) and $2.25

Branding 52

Branding Medicine Marketing Sales 52